NuCana announces a Series B financing of $57 million

NuCana announced the completion of a $57 million Series B financing to fund the development of its portfolio of anti-cancer medicines. The financing was led by new investor, California based venture capital firm Sofinnova Ventures. The deal was completed by substantial investments from the largest shareholder, Paris based Sofinnova Ventures, along side other exisiting investors Morningside Ventures, Alida Capital International and the Scottish Investment Bank.

For the full story please click HERE.